Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | NR1D2 | Q14995 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19993075 | 0.89 | NR1D2 (0.49) | OPRM1NR1D2 | |
| SCHEMBL8302417 | 0.83 | OPRM1 (0.51) | OPRM1 | |
| SCHEMBL13185171 | 0.83 | HTR2A (0.49) | GRIN2B | |
| SCHEMBL28299230 | 0.83 | OPRM1 (0.60) | OPRM1GRIN2BGMNNTP53CYP3A4 | |
| SCHEMBL10260407 | 0.82 | MAOB (0.61) | — | |
| SCHEMBL3634313 | 0.82 | EPHX2 (0.48) | GRIN2BGMNNTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL7296894 | 0.82 | OPRM1 (0.58) | OPRM1GRIN2BGMNNTP53CYP3A4 | |
| SCHEMBL21443558 | 0.81 | CCR3 (0.45) | GRIN2B | |
| SCHEMBL22278193 | 0.81 | NR1D2 (0.45) | NR1D2 | |
| SCHEMBL578726 | 0.81 | SLC6A2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512852-B1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20210017183-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-01-21 | — | — | US | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019180207-A1 | TRAF 6 INHIBITORS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-09-26 | — | — | WO | disclosed |
| WO-2018050286-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-22 | — | — | WO | disclosed |
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| EP-1353905-B1 | PIPERIDINE/PIPERAZINE-TYPE INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2004101507-A2 | N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS | CURACYTE CHEMISTRY GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | OPRM1 935/4885NR1D2 1204/4885GRIN2B 429/4885 |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | OPRM1 3298/4885NR1D2 4619/4885GRIN2B 2630/4885 |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | DNPEP, ANPEP, PEPD | OPRM1 3298/4885NR1D2 4619/4885GRIN2B 2630/4885 |
| US-20210017183-A1 | TRAF 6 INHIBITORS | TRAF2, TRAF6, TRAFD1 | OPRM1 4784/4885NR1D2 3253/4885GRIN2B 4134/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | OPRM1 137/4885NR1D2 632/4885GRIN2B 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.